Abstract: Subject matter of the present invention is a combination medication for use in the treatment of a patient having acute and/or persistent dyspnea comprising at least two of the following components: a beta blocker, and one agent of the group consisting of an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II inhibitor and a combination of angiotensin II inhibitor or an angiotensin receptor-neprilysin inhibitor (ARNi), and mineralo receptor antagonist (MRA), gliflozine, a loop-acting diuretic, wherein a sample of bodily fluid of said patient has a level of BNP>200 pg/mL and/or has a level NT-proBNP>600 pg/mL, and wherein said sample of bodily fluid is selected from the group comprising blood, plasma and serum, and wherein said patient is either a patient with heart failure with left ventricular ejection fraction (LVEF) greater and equal to 40%, preferably 50%, or a patient with no heart failure.

Abstract: A method for subject-specific simulation of foot and/or ankle, the method comprising: receiving in a processor information concerning the subject, using the received information concerning the specific subject, generating at least one subject-specific model of the foot and ankle in relation with the lower limb, comprising bones and soft tissues; wherein the subject-specific model of the foot and ankle is obtained from a combination of a multibody model with a finite elements model; simulating the at least one subject-specific foot and ankle model in an at least one static condition and/or in an at least one dynamic condition using a forward dynamics analysis; and outputting from the processor a set of information obtained from the simulation of the at least one subject-specific foot and ankle model.

Abstract: Example methods, apparatus and system are disclosed relating to a facility for formulating Cell-Based Medicinal Products (CBMPs) in a site where the facility is moved and CBMP formulations are administered. An example facility includes a unitary structure that is assembled together with a vehicle and that houses the working areas and equipment allowing operators to store, count, test, sample, formulate, and/or package CBMPs according to Good Manufacturing Practices. The teachings of the present disclosure relate to a method of providing formulations of a Cell-Based Medicinal Product in sites where the formulations are administered to patients, and from where the facility may be quickly relocated.